The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease
and related human tauopathies. There is a growing body of evidence indicating that …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Alzheimer's disease (AD) pathology is thought to progress from normal cognition through
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …

Vascular contributions to dementia and Alzheimer's disease are increasingly recognized,,,,–.
Recent studies have suggested that breakdown of the blood–brain barrier (BBB) is an early …

Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ) 42/Aβ40 and the concentration of tau
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …

Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …

We developed stable isotope labeling and mass spectrometry approaches to measure the
kinetics of multiple isoforms and fragments of tau in the human central nervous system …

Abstract See Hansson and Mormino (doi: 10.1093/brain/awy065) for a scientific commentary
on this article. Our objective was to compare different whole-brain and region-specific …

Importance A National Institute on Aging–Alzheimer's Association (NIA-AA) workgroup
recently published a research framework in which Alzheimer disease is defined by …